Study Details

Back to Search Results

A study to investigate how safe and effective Solifenacin solution is in treating children/adolescents with symptoms of overactive bladder (OAB) who completed study 905-CL-076

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01655069

Astellas Study ID

The unique identification code given by the study sponsor.

905-CL-077

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2011-002047-10

Follow Trial

Condition

Overactive Bladder Disease

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

5 years - 17 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Oct 2012 - Oct 2014

Masking

None (Open Label)

Enrollment number

148

An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study to investigate how safe and effective Solifenacin solution is in treating children/adolescents with symptoms of overactive bladder (OAB) who completed study 905-CL-076? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site: 6301

Quezon City, Philippines, 1108

Site: 5202

Mexico City, Mexico, 4530

Site: 4901

Marburg, Germany, 35043

Site: 3302

Lille, France, 59037

Site: 5504

Campinas, Brazil, 13024-500

Site: 3101

Nijmegen, Netherlands, 6525 GA

Site: 9104

Dehradun, India, 248140

Site: 1012

Phoenix, United States, 85032

Site: 1014

Albany, United States, 12208

Site: 9109

New Delhi, India, 110001

Site: 9102

Nagpur, India, 440012

Site: 3854

Kharkiv, Ukraine

Site: 4701

Bergen, Norway, 5021

Site: 9004

Kocaeli, Turkey, 41380

Site: 4404

London, United Kingdom, NW1 2BU

Site: 3103

Rotterdam, Netherlands, 3015 CE

Site: 4605

Umea, Sweden, 90185

Site: 9002

Izmir, Turkey, 35100

Site: 3209

Antwerp, Belgium, 2650

Site: 4702

Trondheim, Norway, 7030

Site: 3851

Kyiv, Ukraine, 58001

Site: 4604

Stockholm, Sweden, 17176

Site: 4503

Aalborg, Denmark, DK-9000

Site: 5205

Mexico City, Mexico, C.P.06700

Site: 5502

Sao Paulo, Brazil, 05403-000

Site: 3850

Kiev, Ukraine, 1103

Site: 5505

Sao Jose do Rio Preto, Brazil, 15090-000

Site: 2703

Cape Town, South Africa, 7700

Site: 9001

Ankara, Turkey, 6100

Site: 3201

Gent, Belgium, 9000

Site: 3206

Esneux, Belgium, 4130

Site: 7003

Saint Petersburg, Russian Federation, 194100

Site: 9114

Jaipur, India, 302004

Site: 4903

Bonn, Germany, 53105

Site: 5503

Porto Alegre, Brazil, 90035-003

Site: 8201

Seoul, Republic of Korea, 120752

Site: 4802

Wroclaw, Poland, 50-369

Site: 4906

Frankfurt, Germany, 60435

Site: 1002

Montreal, Canada, H3H 1P3

Site: 2701

Johannesburg, South Africa, 1709

Site: 8207

Seoul, Republic of Korea, 110744

Site: 3202

Antwerp, Belgium, 2020

Site: 9003

Ankara, Turkey, 6100

Site: 3105

Deventer, Netherlands, 7416

Site: 9108

Ahmedabad, India, 380007

Site: 4603

Skovde, Sweden, 54185

Site: 1005

Hamilton, Canada, L8N 3Z5

Site: 3810

Belgrade, Former Serbia and Montenegro, 11 000

Site: 3104

Zwolle, Netherlands, 8011 JW

Site: 5507

Campinas, Brazil, 13087-567

Site: 7002

Moscow, Russian Federation, 123317

Site: 4801

Warsaw, Poland, 04-736

Site: 1009

Durham, United States, 27710

Site: 4402

Leeds, United Kingdom, LS1 3EX

Site: 3205

Leuven, Belgium, 3000

Site: 3208

Charleroi, Belgium, 6000

Site: 5506

Curitiba, Brazil, 80240-060

Site: 4502

Kolding, Denmark, 6000

Site: 4606

Gothenburg, Sweden, 41685

Site: 4804

Lubin, Poland, 20-093

Site: 1008

Tarrytown, United States, 10591

Site: 4601

Jonkoping, Sweden, 55185

Site: 4504

Koge, Denmark, 4600

Site: 1007

Stanford, United States, 94305

Site: 3812

Novi Sad, Former Serbia and Montenegro, 21000

Site: 9005

Istanbul, Turkey

Site: 3811

Belgrade, Former Serbia and Montenegro, 11 000

Site: 3204

Kortrijk, Belgium, 8500

Site: 3301

Paris, France, 75015

Site: 4602

Stockholm, Sweden, 11883

Site: 8203

Daegu, Republic of Korea, 705717

Site: 4403

Leeds, United Kingdom, LS1 3EX

Site: 1006

Shreveport, United States, 71106

Site: 4501

Aarhus N, Denmark, 8200

Site: 3207

Brussels, Belgium, 1020

Site: 3853

Dnipropetrovsk, Ukraine, 49100

Site: 3203

Gent, Belgium, 9000

Site: 8206

Incheon, Republic of Korea, 400-711

Site: 4803

Gdansk, Poland, 80-952

Site: 7005

Moscow, Russian Federation

Site: 4805

Gdansk, Poland, 80-803

Site: 3210

Leuven, Belgium, 3000

Site: 1011

Providence, United States, 02906

Site: 5203

Leon, Mexico, 37000

Site: 7001

Saint Petersburg, Russian Federation, 194100

Site: 9110

Bangalore, India, 560017

Site: 1015

Cincinnati, United States, 45229

Site: 7004

Moscow, Russian Federation, 119991

Site: 4401

Sheffield, United Kingdom, S10 2TH

Site: 5501

Santo Andre, Brazil, 090060-650

Site: 1001

Quebec, Canada, G1V 4G2

Site: 8202

Seoul, Republic of Korea, 156707

Site: 4902

Emmendingen, Germany, 79312

Site: 9105

Hyderabad, India, 500018

Site: 8204

Gwangju, Republic of Korea, 501757

Site: 5204

Mexico City, Mexico, 78218

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo